Cwm, LLC Vir Biotechnology, Inc. Transaction History

Cwm, LLC

$23.3 Billion
Q3 2024

A detailed history of Cwm, LLC transactions in Vir Biotechnology, Inc. stock. As of the latest transaction made, Cwm, LLC holds 1,579 shares of VIR stock, worth $11,684. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,579

Previous 2,228 29.13%

Holding current value

$11,684

Previous $20,000 40.0%

% of portfolio

0.0%

Previous 0.0%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 08, 2024	SELL	$7.26 - $10.7 $4,711 - $6,944	-649 Reduced 29.13%	1,579 $12,000
Q2 2024 Jul 09, 2024	BUY	$7.63 - $12.66 $68 - $113	9 Added 0.41%	2,228 $20,000
Q1 2024 Apr 05, 2024	BUY	$8.6 - $11.9 $3,508 - $4,855	408 Added 22.53%	2,219 $22,000
Q4 2023 Feb 01, 2024	SELL	$7.76 - $10.29 $44,053 - $58,416	-5,677 Reduced 75.81%	1,811 $18,000
Q3 2023 Oct 11, 2023	BUY	$9.14 - $24.62 $61,475 - $165,594	6,726 Added 882.68%	7,488 $70,000
Q2 2023 Aug 03, 2023	BUY	$23.2 - $27.29 $3,132 - $3,684	135 Added 21.53%	762 $19,000
Q1 2023 Apr 28, 2023	BUY	$22.26 - $30.85 $3,628 - $5,028	163 Added 35.13%	627 $15,000
Q4 2022 Feb 01, 2023	BUY	$19.96 - $28.22 $5,169 - $7,308	259 Added 126.34%	464 $12,000
Q3 2022 Oct 27, 2022	SELL	$18.26 - $31.1 $2,739 - $4,665	-150 Reduced 42.25%	205 $4,000
Q2 2022 Jul 28, 2022	BUY	$19.08 - $26.7 $6,773 - $9,478	355 New	355 $9,000
Q1 2022 Apr 21, 2022	SELL	$21.19 - $40.01 $1,292 - $2,440	-61 Closed	0 $0
Q4 2021 Jan 31, 2022	SELL	$30.97 - $54.03 $309 - $540	-10 Reduced 14.08%	61 $3,000
Q1 2021 Apr 27, 2021	SELL	$26.34 - $83.07 $1,896 - $5,981	-72 Reduced 50.35%	71 $4,000
Q4 2020 Jan 27, 2021	BUY	$25.51 - $43.38 $3,647 - $6,203	143 New	143 $4,000

Others Institutions Holding VIR

# of Institutions

218

Shares Held

87M

Call Options Held

127K

Put Options Held

1.19M

View Full List

About Vir Biotechnology, Inc.

Ticker VIR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 132,638,000
Market Cap $982M
Description
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 fo...

More about VIR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Cwm, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cwm, LLC with notifications on news.

Account